<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519543</url>
  </required_header>
  <id_info>
    <org_study_id>TRIO-BD-100</org_study_id>
    <nct_id>NCT02519543</nct_id>
  </id_info>
  <brief_title>Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder</brief_title>
  <acronym>TRIO-BD</acronym>
  <official_title>Treating Insulin Resistance to Improve Outcome in Refractory Bipolar Disorder: a Randomized, Double-blind, Placebo-control Study of the Efficacy of Metformin in Patients With Insulin Resistance and Non-remitting Bipolar Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynthia Calkin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a previous study by Dr. Calkin, the principal investigator of this study, persons with
      bipolar disorder and either type II diabetes or insulin resistance were found to experience
      more severe symptoms of bipolar illness and a lower response to treatment, compared to
      persons with bipolar disorder who did not have type II diabetes or insulin resistance. To
      further explore these findings, the investigators have developed this study to see if adding
      metformin, a drug used to improve the body's use of insulin, may also help improve the
      symptoms of bipolar illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 26-week randomized, double-blind, parallel group prospective study of the
      efficacy of metformin as add-on treatment in patients with insulin resistance ( IR) and
      non-remitting bipolar illness, conducted over three years. The investigators will compare the
      effects of metformin versus placebo on outcome in each patient, while their current optimized
      mood stabilizing treatment as usual (TAU, according to the Canadian Network for Mood and
      Anxiety Treatments [CANMAT]or American Psychiatric Association (APA) guidelines) remains
      unchanged for a period of at least 8 weeks prior to and throughout the study. Patients will
      undergo a baseline assessment and then be randomized to treatment with placebo or metformin
      with titration to full dose after 2 weeks. Patients will remain on full treatment for 24
      weeks thereafter (total trial duration of 26 weeks for each patient). The investigators will
      compare response to metformin versus placebo (measured by Montgomery-Çºsberg Depression Rating
      Scale [MADRS] as the primary outcome).

      Subjects: Enrolment of 110 subjects with IR and non-remitting bipolar depression will be
      recruited over three years from 2 sites, the primary site in Halifax, Nova Scotia, Canada and
      a second site in Pittsburgh, Pennsylvania, USA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery- Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will study the effect of metformin on mood symptoms using this scale . We will compare improvement in the MADRS with the Homeostatic Model Assessment- Insulin Resistance (HOMA-IR) to determine if degree of improvement in symptoms correlates with degree of improvement in insulin resistance (IR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inventory of Depressive Symptomatology-Self Rating (IDS-SR)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will examine the effect of metformin on mood and anxiety symptoms using this rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will We will examine the effect of metformin on mood and anxiety symptoms using this rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will examine the effect of metformin on mood and anxiety symptoms using this rating scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression modified for use in Bipolar Disorder (CGI-BP)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will use this scale to assess overall psychiatric morbidity and severity of illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Functioning (GAF)</measure>
    <time_frame>26 weeks</time_frame>
    <description>We will use this scale to assess overall psychiatric morbidity and severity of illness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator to be given twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 1500 mg daily to be given as follows: 500mg am and 1000 mg pm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to be given twice daily, once with breakfast and once with supper</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>active experimental drug to be given twice a day, 500 mg with breakfast and 1,000 mg with supper.</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>Metformin Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. diagnosis of BD I or II

          3. non-remitting BD as defined by the presence of mood symptoms of at least moderate
             severity, indicated by a MADRS score &gt; 15 despite being on optimal treatment according
             to the CANMAT/APA guidelines and

          4. HOMA-IR &gt; 1.8, indicating IR (subjects will haveFasting PLasma Glucose (FPG) and
             Fasting Serum Insulin (FSI) testing done to determine whether they have Insulin
             Resistance (IR) or Type II Diabetes (T2D).

        Exclusion Criteria:

          1. Diagnoses of organic mood disorder, mood disorder not otherwise specified, alcohol
             dependence or T2D

          2. presence of rapid cycling (by the Diagnostic and Statistical Manual of Mental
             Disorders (DSM-5 criteria), mania, (indicated by a Young Mania Rating Scale [YMRS]
             score &gt; 15), or suicide ideation (current score of 5 on the Suicidal Ideation section
             of the Columbia-Suicide Severity Rating Scale (C-SSRS)

          3. patients receiving metformin &lt; 3 months prior to study entry

          4. metformin allergy or sensitivity

          5. metformin contraindicated where liver function tests &gt; three times the upper limit of
             normal (alanine transaminase (ALT) &gt; 162 U/L, aspartate transaminase (AST) &gt; 69 U/L at
             NSHA), estimated glomerular filtration rate (eGFR) &lt; 30, complete blood count (CBC)
             revealing megaloblastic anemia or pre-existing untreated B12 deficiency

          6. pregnancy or breastfeeding

          7. lactose intolerance, or 8) patient lacks full capacity to consent to study
             participation -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Calkin, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy Chengappa, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Calkin, MD FRCPC</last_name>
    <phone>902-473-2585</phone>
    <email>cindy.calkin@NSHealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie S Garnham, RNBN</last_name>
    <phone>902-473-7144</phone>
    <email>jgarnham@dal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2593</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Chengappa, MD FRCPC</last_name>
      <email>chengappakn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Schlicht, BN</last_name>
      <phone>412-246-5258</phone>
      <email>schlpx@UPMC.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Roy Chengappa, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority - Dept. of Psychiatry</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie S Garnham, BN</last_name>
      <phone>(902) 473 7144</phone>
      <email>jgarnham@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Cynthia Calkin, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://apps.webofknowledge.com/full_record.do?product=UA&amp;search_mode=GeneralSearch&amp;qid=1&amp;SID=2CRUvkzBT6AQyUenrvK&amp;page=2&amp;doc=11</url>
    <description>The risk of insulin resistance and type 2 diabetes mellitus in bipolar disorder</description>
  </link>
  <link>
    <url>http://ac.els-cdn.com.ezproxy.library.dal.ca/S0924977X13705789/1-s2.0-S0924977X13705789-main.pdf?_tid=234a7e9a-3c2e-11e5-ace4-00000aab0f01&amp;acdnat=1438860636_5aecad769a45feae96b677c0ccb908cc</url>
    <description>Are comorbid insulin resistance and type II diabetes risk factors for refractory bipolar illness?</description>
  </link>
  <reference>
    <citation>Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, O'Donovan MC, Alda M. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015 Jan;206(1):52-7. doi: 10.1192/bjp.bp.114.152850. Epub 2014 Oct 16.</citation>
    <PMID>25323142</PMID>
  </reference>
  <reference>
    <citation>Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003 Aug;48(7):458-61.</citation>
    <PMID>12971015</PMID>
  </reference>
  <reference>
    <citation>Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013 Mar;45(2):171-81. doi: 10.3109/07853890.2012.687835. Epub 2012 May 24. Review.</citation>
    <PMID>22621171</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Cynthia Calkin</investigator_full_name>
    <investigator_title>Cynthia Calkin, Assisant Professor, Dalhousie University, Nova Scotia Health Authority</investigator_title>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

